1. Home
  2. ELBM vs TIL Comparison

ELBM vs TIL Comparison

Compare ELBM & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Electra Battery Materials Corporation

ELBM

Electra Battery Materials Corporation

HOLD

Current Price

$0.62

Market Cap

62.2M

Sector

Miscellaneous

ML Signal

HOLD

Logo Instil Bio Inc.

TIL

Instil Bio Inc.

HOLD

Current Price

$8.20

Market Cap

54.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ELBM
TIL
Founded
2011
2018
Country
Canada
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
62.2M
54.8M
IPO Year
2022
2021

Fundamental Metrics

Financial Performance
Metric
ELBM
TIL
Price
$0.62
$8.20
Analyst Decision
Strong Buy
Buy
Analyst Count
2
3
Target Price
$2.15
$125.00
AVG Volume (30 Days)
1.0M
27.8K
Earning Date
05-12-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
6.06
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$28.71
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.50
$5.67
52 Week High
$8.70
$42.75

Technical Indicators

Market Signals
Indicator
ELBM
TIL
Relative Strength Index (RSI) 49.92 51.12
Support Level $0.55 $8.07
Resistance Level $0.65 $8.30
Average True Range (ATR) 0.03 0.23
MACD -0.00 0.02
Stochastic Oscillator 44.09 78.74

Price Performance

Historical Comparison
ELBM
TIL

About ELBM Electra Battery Materials Corporation

Electra Battery Materials Corp is building North America's fully integrated, localized, and environmentally sustainable battery materials park. Electra Battery Materials is an integral part of the North American battery supply chain, providing low-carbon, sustainable, and traceable raw materials for the region's fast growing electric vehicle industry. The Company's operating segments are Refinery, Exploration and Evaluation, Corporate and Other.

About TIL Instil Bio Inc.

Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.

Share on Social Networks: